COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
复制标题
DOI：
10.1038/s41467-021-26354-0
复制
发表时间：
2021-10-20
影响因子：
16.6
通讯作者：
Le Grand R
中科院分区：
文献类型：
--
作者：
Maisonnasse P;Aldon Y;Marc A;Marlin R;Dereuddre-Bosquet N;Kuzmina NA;Freyn AW;Snitselaar JL;Gonçalves A;Caniels TG;Burger JA;Poniman M;Bontjer I;Chesnais V;Diry S;Iershov A;Ronk AJ;Jangra S;Rathnasinghe R;Brouwer PJM;Bijl TPL;van Schooten J;Brinkkemper M;Liu H;Yuan M;Mire CE;van Breemen MJ;Contreras V;Naninck T;Lemaître J;Kahlaoui N;Relouzat F;Chapon C;Ho Tsong Fang R;McDanal C;Osei-Twum M;St-Amant N;Gagnon L;Montefiori DC;Wilson IA;Ginoux E;de Bree GJ;García-Sastre A;Schotsaert M;Coughlan L;Bukreyev A;van der Werf S;Guedj J;Sanders RW;van Gils MJ;Le Grand R
迫切需要针对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的有效治疗。单克隆抗体在患者身上显示出有希望的结果。在这里，我们评估了 COVA1-18（一种针对 B.1.1.7 分离株的高效中和抗体）的体内预防和治疗效果。在预防和治疗环境中，在接受治疗的 hACE2 小鼠的肺部中仍然检测不到 SARS-CoV-2。治疗还会导致叙利亚仓鼠肺部病毒载量减少。在对食蟹猴进行高剂量 SARS-CoV-2 攻击前一天以 10 mg kg-1 给药时，COVA1-18 在上呼吸道区室中表现出非常强的抗病毒活性。使用数学模型，我们估计 COVA1-18 可将这些隔室中的病毒感染性降低 95% 以上，从而预防淋巴细胞减少和广泛的肺部病变。我们的研究结果表明，COVA1-18 在三个临床前模型中具有很强的抗病毒活性，可能是进一步临床评估的有价值的候选者。单克隆抗体在治疗 Covid-19 患者方面显示出巨大的前景。 Maisonnasse、Aldon 及其同事报告了 COVA1-18 的临床前结果，并证明它可以降低三种动物模型中的病毒感染性，对猕猴上呼吸道的疗效超过 95%。
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation. Monoclonal antibodies show great promise in treating Covid-19 patients. Here, Maisonnasse, Aldon and colleagues report pre-clinical results for COVA1-18 and demonstrate that it reduces viral infectivity in three animal models with over 95% efficacy in macaques upper respiratory tract.
登录
查看更多内容
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
32.4
作者：
Liu, Hejun;Wu, Nicholas C;Wilson, Ian A
通讯作者：
Wilson, Ian A
影响因子：
13.6
作者：
Mansbach RA;Chakraborty S;Nguyen K;Montefiori DC;Korber B;Gnanakaran S
通讯作者：
Gnanakaran S
影响因子：
17.1
作者：
Jones BE;Brown-Augsburger PL;Corbett KS;Westendorf K;Davies J;Cujec TP;Wiethoff CM;Blackbourne JL;Heinz BA;Foster D;Higgs RE;Balasubramaniam D;Wang L;Zhang Y;Yang ES;Bidshahri R;Kraft L;Hwang Y;Žentelis S;Jepson KR;Goya R;Smith MA;Collins DW;Hinshaw SJ;Tycho SA;Pellacani D;Xiang P;Muthuraman K;Sobhanifar S;Piper MH;Triana FJ;Hendle J;Pustilnik A;Adams AC;Berens SJ;Baric RS;Martinez DR;Cross RW;Geisbert TW;Borisevich V;Abiona O;Belli HM;de Vries M;Mohamed A;Dittmann M;Samanovic MI;Mulligan MJ;Goldsmith JA;Hsieh CL;Johnson NV;Wrapp D;McLellan JS;Barnhart BC;Graham BS;Mascola JR;Hansen CL;Falconer E
通讯作者：
Falconer E
REGN-COV2抗体预防和治疗恒河猕猴和仓鼠中的SARS-COV-2感染。
DOI：
10.1126/science.abe2402
发表时间：
2020-11-27
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Baum A;Ajithdoss D;Copin R;Zhou A;Lanza K;Negron N;Ni M;Wei Y;Mohammadi K;Musser B;Atwal GS;Oyejide A;Goez-Gazi Y;Dutton J;Clemmons E;Staples HM;Bartley C;Klaffke B;Alfson K;Gazi M;Gonzalez O;Dick E Jr;Carrion R Jr;Pessaint L;Porto M;Cook A;Brown R;Ali V;Greenhouse J;Taylor T;Andersen H;Lewis MG;Stahl N;Murphy AJ;Yancopoulos GD;Kyratsous CA
通讯作者：
Kyratsous CA